177Lu-PD-29875 / PeptiDream - LARVOL DELTA

Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models. (SNMMI 2025) - "To assess biodistribution, 64Cu-PD-29875, 177Lu-PD-29875 or 225Ac-PD-29875 was dosed to BxPC3-CLDN18.2 xenograft mice, and the percentage of injected dose per gram of tissue in tumors and major organs was quantified by cut and count method. PD-29875 is a promising radiotheranostic peptide for CLDN18.2-expressing solid tumors including pancreatic cancer."

Clinical • Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

Non-clinical pharmacology research of PD-29875, first-in-class Claudin 18.2-targeting radiotheranostic peptide, in pancreatic cancer models. (SNMMI 2025) - "PD-29875 is a promising radiotheranostic peptide for CLDN18.2-expressing solid tumors including pancreatic cancer."

Clinical • Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

First-in-class Claudin 18.2 targeting radiopeptide, 64Cu-PD-29875 and 177Lu-PD-29875, exhibit promising theranostic potential in a pancreatic cancer xenograft model (AACR 2025) - "PD-29875 has preferable properties for imaging and therapy with radionuclides for theranostic use in CLDN18.2 expressing solid tumors including pancreatic cancer."

Preclinical • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18